Table 4.
Adverse Events
| Total N(%) | Grade | |||
|---|---|---|---|---|
| 1 | 2 | 3–4 | ||
| Apatinib alonea | 45 (100%) | |||
| Fatigue | 8(17.8%) | 5 | 2 | 1 |
| Hypertension | 35(77.8%) | 27 | 3 | 5 |
| Proteinuria | 4(8.9%) | 3 | 1 | |
| Hand-foot syndrome | 12(26.7%) | 10 | 2 | |
| Diarrhea | 9(20%) | 5 | 3 | 1 |
| Weight loss | 19(42.2%) | 17 | 2 | |
| Hair hypopigmentation | 25(55.6%) | 20 | 5 | |
| Anorexia | 17(37.8%) | 10 | 4 | 3 |
| Rash or desquamation | 26(57.8%) | 15 | 9 | 2 |
| Mucositis | 2(4.4%) | 2 | ||
| Pneumothorax | 9(20%) | 3 | 6 | |
| Wound-healing problems | 6(13.3%) | 1 | 5 | |
| Elevated Aminotransferase or bilirubin | 3(6.7%) | 2 | 1 | |
| Thrombocytopenia | 7(15.6%) | 5 | 1 | 1 |
| Seizure-like attack | 1(2.3%) | 1 | ||
| Pancreatitis | 1(2.2%) | 1 | ||
| Anemia | 2(4.4%) | 2 | ||
| Cranial neuritis | 1(2.3%) | 1 | ||
| Apatinib + everolimusb | 7 (100%) | |||
| Mucositis | 7(100%) | 2 | 4 | 1 |
| Hypertension | 4(57.1%) | 2 | 2 | |
| Rash or desquamation | 5(71.4%) | 2 | 3 | |
| Gastrointestinal uncomfort | 1(14.3%) | 1 | ||
| Apatinib + GTc | 5 (100%) | |||
| Hypertension | 1(20%) | 1 | ||
| Rash or desquamation | 2(40%) | 2 | ||
| Wound-healing problems | 1(20%) | 1 | ||
| Thrombocytopenia | 2(40%) | 1 | 1 | |
aApatinib alone: apatinib 500-750 mg/d according to the patient’s weight
bApatinib + everolimus: apatinib 250–500 mg/d + everolimus 5 mg/d according to the patient’s weight
cGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 days